Dexamethasone Suppresses Tumor Necrosis Factor-α-Induced Apoptosis in Osteoblasts: Possible Role for Ceramide1

• Published in: Endocrinology (Philadelphia) 2000-08, Vol.141 (8), p.2904-2913
• Main Authors: Chae, Han Jung, Chae, Soo Wan, Kang, Jang Sook, Bang, Byung Gwan, Cho, Seoung Bum, Park, Rae Kil, So, Hong Seob, Kim, Yong Kwang, Kim, Hyung Min, Kim, Hyung Ryong
• Format: Article
• Language: English
• ISSN: 0013-7227; 1945-7170
• DOI: 10.1210/endo.141.8.7604

Ceramide has been proposed as a second messenger molecule implicated in a variety of biological processes, including apoptosis. Recently, it has been reported that tumor necrosis factor-α (TNF-α) activates the release of ceramide and that ceramide acts as a mediator for the TNF-α-induced stimulation of the binding affinity of nuclear factor-κB (NF-κB), a ubiquitous transcription factor of particular importance in immune and inflammatory responses. In this study we demonstrate that dexamethasone, which reduces the production of ceramide, significantly inhibits TNF-α-induced activation of NF-κB, c-Jun N-terminal kinase, also known as stress-activating protein kinase, caspase-3-like cysteine protease, redistribution of cytochrome c, and apoptosis in MC3T3E1 osteoblasts. Compared with TNF-α-induced JNK activation, ceramide elicits a more rapid activation of JNK within 30 min. C2-ceramide activates NF-κB and caspase-3 like protease to the same degree and with kinetics similar to those of TNF-α. This study provides evidence that the release of ceramide may be required as a second messenger in TNF-α-induced apoptosis. These results also suggest a regulatory role for dexamethasone in TNF-α-induced apoptosis via inhibition of ceramide release. Therefore, our in vitro results suggest that therapies targeted at the inhibition of ceramide release may abrogate inflammatory processes in TNF-α-related diseases, including rheumatoid arthritis and periodontitis.